The proteomic analysis of cisplatin resistance in breast cancer cells

Oncology Research

Volumn 16, Issue 11, 2007, Pages 497-506

  Smith, Laura ^a   Welham, Kevin J ^a   Watson, Mark B ^a   Drew, Philip J ^a   Lind, Michael J ^a   Cawkwell, Lynn ^a,b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Biomarkers; Breast cancer; Chemotherapy; Cisplatin; Proteomics

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE 15; ALPHA TROPOMYOSIN; BETA TUBULIN; BETA TUBULIN TYPE 3; CISPLATIN; CYTOKERATIN 17; ELECTRON TRANSFERRING FLAVOPROTEIN; ELECTRON TRANSFERRING FLAVOPROTEIN BETA POLYPEPTIDE ISOFORM 1; GELATINASE B; GLUTATHIONE TRANSFERASE M3; HEAT SHOCK PROTEIN 27; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A3; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 3; PEPTIDE; PEPTIDYL PROLYL ISOMERASE A; PEPTIDYL PROPYL ISOMERASE B; PEROXIREDOXIN; PEROXIREDOXIN 4; PROTEASOME; PROTEASOME BETA1; RIBOSOME PROTEIN; SYNAPSIN I; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN MCF 7; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

EID: 38949198706     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504007783438358     Document Type: Article

References (27)

1. Martin, M. Platinum compounds in the treatment of advanced breast cancer. Clin. Breast Cancer 2:190-208; 2001.
2. Vassilomanolakis, M.; Koumakis, G.; Barbounis, V.; Demiri, M.; Panopoulos, C.; Chrissohoou, M.; Apostolikas, N.; Efremidis, A. P. First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer. Breast 4:136-141; 2005.
3. Chehal, A.; Taher, A.; Khalil, M.; Shameseddine, A. Cisplatin plus vinorelbine (PVn) as a salvage regimen for refractory breast cancer. Breast 13:421-424; 2004.
4. Park, S. H.; Cho, E. K.; Bang, S. M.; Shin, D. B.; Lee, J. H.; Lee, Y. D. Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial. BMC Cancer 5:21-26; 2005.
5. Smith, L.; Lind, M. J.; Welham, K. J.; Cawkwell, L. Cancer proteomics and its application to discovery of therapy response markers in human cancer. Cancer 107:232-241; 2006.
6. Watson, M. B.; Lind, M. J.; Cawkwell, L. Establishment of in-vitro models of chemotherapy resistance. Anticancer Drugs 18:749-754; 2007.
7. Watson, M. B.; Lind, M. J.; Smith, L.; Drew, P. J.; Cawkwell, L. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model. Acta Oncol. 46:651-658; 2007.
8. Wilkins, M. R.; Appel, R. D.; Van Eyk, J. E.; Chung, M. C.; Gorg, A.; Hecker, M.; Huber, L. A.; Langen, H.; Link, A. J.; Paik, Y. K.; Patterson, S. D.; Pennington, S. R.; Rabilloud, T.; Simpson, R. J.; Weiss, W.; Dunn, M. J. Guidelines for the next 10 years of proteomics. Proteomics 6:4-8; 2006.
9. Moriuchi, S.; Shimizu, K.; Miyao, Y.; Yamada, M.; Ohkawa, M.; Hayakawa, T. In vitro assessment for neurotoxicity of antitumor agents before local administration into central nervous system. Anticancer Res. 16:135-140; 1996.
10. Schondorf, T.; Kurbacher, C. M.; Gohring, U. J.; Benz, C.; Becker, M.; Sartorius, J.; Kolhagen, H.; Mallman, P.; Neumann, R. Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res. 22:2199-2203; 2002.
11. Keepers, Y. P.; Pizao, P. E.; Peters, G. J.; van Ark-Otte, J.; Winograd, B.; Pinedo, H. M. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer 27:897-900; 1991.
12. Katabami, M.; Fujita, H.; Honke, K.; Makita, A.; Akita, H.; Miyamoto, H.; Kawakami, Y.; Kuzumaki, N. Marked reduction of type I keratin (K14) in cisplatin-resistant human lung squamous-carcinoma cell lines. Biochem. Pharmacol. 45:1703-1710; 1993.
13. Parekh, H. K.; Simpkins, H. The differential expression of cytokeratin 18 in cisplatin-sensitive and -resistant human ovarian adenocarcinoma cells and its association with drug sensitivity. Cancer Res. 55:5203-5206; 1995.
14. Shen, D. W.; Liang, X. J.; Gawinowicz, M. A.; Gottesman, M. M. Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol. Pharmacol. 66:789-793; 2004.
15. Finkel, T. Oxygen radicals and signalling. Curr. Opin. Cell Biol. 10:248-253; 1998.
16. Rhee, S. G.; Chae, H. Z.; Kim, K. Peroxiredoxins: A historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic. Biol. Med. 38:1543-1552; 2005.
17. Chung, Y. M.; Yoo, Y. D.; Park, J. K.; Kim, Y. T.; Kim, H. J. Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res. 21:1129-1133; 2001.
18. Mosser, D. D.; Morimoto, R. I. Molecular chaperones and the stress of oncogenesis. Oncogene 23:2907-2918; 2004.
19. Yamamoto, K.; Okamoto, A.; Isonishi, S.; Ochiai, K.; Ohtake, Y. Heat shock protein 27 was upregulated in cisplatin resistant human ovarian tumour cell line and associated with cisplatin resistance. Cancer Lett. 168:173-181; 2001.
20. Arts, H. J.; Hollema, H.; Lemstra, W.; Willemse, P. H.; De Vries, E. G.; Kampinga, H. H.; Van der Zee, A. G. Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: Relation to response to chemotherapy and prognosis. Int. J. Cancer 84:234-238; 1999.
21. Hettinga, J. V.; Lemstra, W.; Meijer, C.; et al. Heat-shock protein expression in cisplatin-sensitive and -resistant human tumor cells. Int. J. Cancer 67:800-807; 1996.
22. Townsend, D. M.; Findlay, V. L.; Tew, K. D. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol. 401:287-307; 2005.
23. Hirano, T.; Kato, H.; Maeda, M.; Gong, Y.; Shou, Y.; Nakamura, M.; Maeda, J.; Yashima, K.; Kato, Y.; Akimoto, S.; Ohira, T.; Tsuboi, M.; Ikeda, N. Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker. Int. J. Cancer 117:460-468; 2005.
24. Townsend, A. J.; Tu, C. P.; Cowan, K. H. Expression of human mu or alpha class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: Effect on cellular sensitivity to cytotoxic agents. Mol. Pharmacol. 41:230-236; 1992.
25. Kearns, P. R.; Chrzanowska-Lightowlers, Z. M. A.; Pieters, R.; Veerman, A.; Hall, A. G. Mu class glutathione S-transferase mRNA isoform expression in acute lymphoblastic leukaemia. Br. J. Haematol. 120:80-88; 2003.
26. Le Moguen, K.; Lincet, H.; Deslandes, E.; Hubert-Roux, M.; Lange, C.; Poulain, L.; Gauduchon, P.; Baudin, B. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics 6:5183-5192; 2006.
27. Bahia, H.; Ashman, J. N.; Cawkwell, L.; Lind, M.; Monson, J. R.; Drew, P. J.; Greenman, J. Karyotypic variation between independently cultured strains of the cell line MCF-7 identified by multicolour fluorescence in situ hybridization. Int. J. Oncol. 20:489-494; 2002.